ClinicaliQ Trial Snapshot
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation — Recruiting • Phase III • Oncology • NCT07211958.
- What is being tested: Revumenib, a menin inhibitor, combined with intensive chemotherapy versus chemotherapy alone in newly diagnosed AML patients with NPM1 mutations, evaluating efficacy and safety outcomes.
- Patient eligibility overview: Adults with newly diagnosed acute myeloid leukaemia harbouring NPM1 mutations who are candidates for intensive chemotherapy treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Eligibility Snapshot
- Key Inclusion Criteria: * Participants must have newly diagnosed and previously untreated AML and be candidates for intensive chemotherapy. * Presence of an NPM1 mutation. * Eastern Cooperative Oncology Group performance status ≤2 (≤1 if >65 years old); Karnofsky or Lansky ≥40. * Have a life expectancy of ≥3 months as judged by the Investigator. * Negative serum pregnancy test. * Adequate liver, kidney, and cardiac function. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.